Immunitybio Inc (IBRX)

$2.11 +0.11 (5.50%)
Market Cap 2.03B
Revenue (ttm) 14.75M
Net Income (ttm) -413.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,803.80%
Debt to Equity Ratio -0.96
Volume 5,250,267
Avg Vol 9,867,236
Day's Range N/A - N/A
Shares Out 984.97M
Stochastic %K 14%
Beta 0.29
Analysts Strong Sell
Price Target $10.20

Company Profile

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead b...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 696 5235
Address:
3530 John Hopkins Court, San Diego, United States
factme
factme Nov. 14 at 7:39 PM
$IBRX
0 · Reply
svertical1
svertical1 Nov. 14 at 7:39 PM
$IBRX Long list of wins for IBRX to be down 55% in last 12 months. •Anktiva FDA approval •rBCG / India news •CRL resolution •Numerous Trial results (lung, Covid, lymphoma,GBM, etc) •EAP for ‘all cancer patients’ •RMAT •UK Approval •Deal on production facility •Saudi MOU •PSS Podcast tour •Trump Admin accolades •Quarterly Rev Increases •Massive changes at HHS/FDA conducive for drugs like Bioshield (MAHA, Vouchers, Plausible Mechanism of effectiveness, Biotech friendly leadership) •etc
0 · Reply
Knockwurst89
Knockwurst89 Nov. 14 at 7:39 PM
$IBRX Shorts and hedgies want to keep price increase down a little so attention not drawn to retailers over weekend.
0 · Reply
factme
factme Nov. 14 at 7:33 PM
$IBRX perkins!!! Imma ready!!!
0 · Reply
svertical1
svertical1 Nov. 14 at 7:32 PM
$IBRX Near term catalyst: •EU Approval •Saudi MOU details Anytime catalysts: •FDA Label expansion (Papillary, Lung, Covid, etc) •FDA approval for ALL Cancer or Lymphopenia •Ex-US deal •Major analyst coverage •MAHA/NIH Grant •Trump Admin Equity Investment •Trial results •BP investment/ deal •SEC Investigation- Naked shorting/ price manipulation •Partners deal
0 · Reply
kcajsnikrep
kcajsnikrep Nov. 14 at 7:32 PM
$IBRX Sorry, not good enough for Korean cheerleaders. Barring a close above $2.20 today, I will withold. Maybe next week.
0 · Reply
TSLA_S3XY
TSLA_S3XY Nov. 14 at 7:30 PM
$IBRX We Can Do It. Slap Ask. $2.20 In Sight
0 · Reply
JJPlus7
JJPlus7 Nov. 14 at 7:29 PM
$IBRX IF...everything works out for the Bulls here, then we can only hope the Bears invest in Depends..
0 · Reply
havingfunDH
havingfunDH Nov. 14 at 7:26 PM
$IBRX I’m very excited for next week. I’m trying to lower my expectations so I don’t end up disappointed. Hoping for the best. Happy weekend to you all!
1 · Reply
PoorOffTrading
PoorOffTrading Nov. 14 at 7:07 PM
$IBRX I would sell if I were you.
1 · Reply
Latest News on IBRX
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

Nov 13, 2025, 9:00 AM EST - 1 day ago

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Nov 4, 2025, 10:12 PM EST - 9 days ago

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

Oct 22, 2025, 1:42 PM EDT - 23 days ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS PLUG RKT RXRX

ImmunityBio: A Small Bet Is Warranted

Oct 3, 2025, 1:24 PM EDT - 6 weeks ago

ImmunityBio: A Small Bet Is Warranted

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

Sep 11, 2025, 12:26 PM EDT - 2 months ago

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Sep 8, 2025, 8:30 AM EDT - 2 months ago

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

Aug 26, 2025, 8:30 AM EDT - 2 months ago

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

Aug 19, 2025, 8:30 AM EDT - 3 months ago

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

Aug 13, 2025, 8:30 AM EDT - 3 months ago

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

Aug 11, 2025, 8:30 AM EDT - 3 months ago

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Aug 5, 2025, 7:00 AM EDT - 3 months ago

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

Jul 25, 2025, 6:03 AM EDT - 4 months ago

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

Jul 25, 2025, 6:00 AM EDT - 4 months ago

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

Jul 21, 2025, 10:45 AM EDT - 4 months ago

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jul 7, 2025, 9:43 PM EDT - 4 months ago

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

Jun 12, 2025, 9:09 AM EDT - 5 months ago

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Jun 3, 2025, 8:45 AM EDT - 5 months ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

Jun 2, 2025, 9:00 AM EDT - 5 months ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 27, 2025, 8:00 AM EDT - 6 months ago

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 12, 2025, 6:30 AM EDT - 6 months ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

May 5, 2025, 5:05 PM EDT - 6 months ago

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

May 5, 2025, 9:21 AM EDT - 6 months ago

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

May 5, 2025, 6:30 AM EDT - 6 months ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 29, 2025, 12:50 PM EDT - 7 months ago

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Apr 28, 2025, 8:30 AM EDT - 7 months ago

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Apr 21, 2025, 4:21 PM EDT - 7 months ago

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Apr 15, 2025, 8:00 AM EDT - 7 months ago

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

Apr 8, 2025, 7:30 AM EDT - 7 months ago

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Apr 7, 2025, 5:00 AM EDT - 7 months ago

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

ImmunityBio: Taking Care Of Business

Apr 3, 2025, 5:54 PM EDT - 8 months ago

ImmunityBio: Taking Care Of Business

ImmunityBio to Host Investor Day

Mar 26, 2025, 6:00 AM EDT - 8 months ago

ImmunityBio to Host Investor Day

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

Mar 13, 2025, 9:00 AM EDT - 8 months ago

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 7, 2025, 1:47 AM EST - 9 months ago

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

Mar 3, 2025, 7:30 AM EST - 9 months ago

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Feb 27, 2025, 7:10 PM EST - 9 months ago

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

Feb 19, 2025, 9:00 AM EST - 9 months ago

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feb 13, 2025, 3:05 PM EST - 9 months ago

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Jan 29, 2025, 8:30 AM EST - 10 months ago

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jan 27, 2025, 9:00 AM EST - 10 months ago

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 17, 2025, 2:05 PM EST - 10 months ago

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

Jan 16, 2025, 2:25 PM EST - 10 months ago

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Jan 15, 2025, 5:20 PM EST - 10 months ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Jan 15, 2025, 5:20 PM EST - 10 months ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Jan 6, 2025, 9:00 AM EST - 11 months ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

Dec 16, 2024, 12:24 AM EST - 11 months ago

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

Dec 13, 2024, 2:40 PM EST - 1 year ago

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Dec 12, 2024, 8:00 AM EST - 1 year ago

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Dec 11, 2024, 7:30 AM EST - 1 year ago

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Dec 10, 2024, 4:24 PM EST - 1 year ago

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

factme
factme Nov. 14 at 7:39 PM
$IBRX
0 · Reply
svertical1
svertical1 Nov. 14 at 7:39 PM
$IBRX Long list of wins for IBRX to be down 55% in last 12 months. •Anktiva FDA approval •rBCG / India news •CRL resolution •Numerous Trial results (lung, Covid, lymphoma,GBM, etc) •EAP for ‘all cancer patients’ •RMAT •UK Approval •Deal on production facility •Saudi MOU •PSS Podcast tour •Trump Admin accolades •Quarterly Rev Increases •Massive changes at HHS/FDA conducive for drugs like Bioshield (MAHA, Vouchers, Plausible Mechanism of effectiveness, Biotech friendly leadership) •etc
0 · Reply
Knockwurst89
Knockwurst89 Nov. 14 at 7:39 PM
$IBRX Shorts and hedgies want to keep price increase down a little so attention not drawn to retailers over weekend.
0 · Reply
factme
factme Nov. 14 at 7:33 PM
$IBRX perkins!!! Imma ready!!!
0 · Reply
svertical1
svertical1 Nov. 14 at 7:32 PM
$IBRX Near term catalyst: •EU Approval •Saudi MOU details Anytime catalysts: •FDA Label expansion (Papillary, Lung, Covid, etc) •FDA approval for ALL Cancer or Lymphopenia •Ex-US deal •Major analyst coverage •MAHA/NIH Grant •Trump Admin Equity Investment •Trial results •BP investment/ deal •SEC Investigation- Naked shorting/ price manipulation •Partners deal
0 · Reply
kcajsnikrep
kcajsnikrep Nov. 14 at 7:32 PM
$IBRX Sorry, not good enough for Korean cheerleaders. Barring a close above $2.20 today, I will withold. Maybe next week.
0 · Reply
TSLA_S3XY
TSLA_S3XY Nov. 14 at 7:30 PM
$IBRX We Can Do It. Slap Ask. $2.20 In Sight
0 · Reply
JJPlus7
JJPlus7 Nov. 14 at 7:29 PM
$IBRX IF...everything works out for the Bulls here, then we can only hope the Bears invest in Depends..
0 · Reply
havingfunDH
havingfunDH Nov. 14 at 7:26 PM
$IBRX I’m very excited for next week. I’m trying to lower my expectations so I don’t end up disappointed. Hoping for the best. Happy weekend to you all!
1 · Reply
PoorOffTrading
PoorOffTrading Nov. 14 at 7:07 PM
$IBRX I would sell if I were you.
1 · Reply
Day_trading_group_
Day_trading_group_ Nov. 14 at 6:37 PM
$JFBR $CLIK $BBAI $IBRX Trend reversal https://stocktwits.com/Day_trading_group_/message/636248676
0 · Reply
Jeslane1378
Jeslane1378 Nov. 14 at 6:35 PM
$IBRX
1 · Reply
elitechrisvp
elitechrisvp Nov. 14 at 6:35 PM
$IBRX very
0 · Reply
fwbavp
fwbavp Nov. 14 at 6:33 PM
$IBRX The FDA's newly proposed Plausible Mechanism Pathway would be HUGE for ImmunityBio! It would allow them to bring their products to market in many different indications and without the need for time consuming, costly randomized trials. This would save years of time and countless lives! I can't stress enough how big of a development this could be if it goes into effect. Overall, this could de-risk ImmunityBio's pipeline, attract investment, and position the company as a leader in immune-oncology, especially given Patrick Soon-Shiong's influence in pushing for regulatory flexibility. I highly recommend reading Grok's take on it and the timing behind it going from proposal to policy:
0 · Reply
IBRXrallypossum002100
IBRXrallypossum002100 Nov. 14 at 6:31 PM
$IBRX The # of days until it went into effect, as stated on the SEC filing, lines up curiously with the Saudi visit. TBD
0 · Reply
Biofrog
Biofrog Nov. 14 at 6:06 PM
$IBRX WTF with this who needs National Priority Vouchers? Great development!!
1 · Reply
RKwine
RKwine Nov. 14 at 6:04 PM
$IBRX https://www.facebook.com/share/1DAGYMcBhZ/?mibextid=wwXIfr
0 · Reply
Lucky411
Lucky411 Nov. 14 at 6:04 PM
$IBRX https://youtu.be/CC3I6bdWI_s?si=LEGBxgOEyOmNgtzj
0 · Reply
factme
factme Nov. 14 at 6:00 PM
$IBRX Perkins!!
0 · Reply
Mclightning
Mclightning Nov. 14 at 5:59 PM
$IBRX lots of volume on $2.5C for next week
0 · Reply
IBBearish
IBBearish Nov. 14 at 5:45 PM
$IBRX Monday this will be down 10%
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 5:37 PM
Hedge Alert Live - Protect Your Portfolio Contract: $IBRX $2.00 Put · NOV 21, 2025 Exp Entry Price: $0.10 - $0.15 Exit Price Target: $0.22 Profit Margin: +122% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply